CymaBay Therapeutics (CBAY)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CymaBay Therapeutics (CBAY) trades at $32.48 with AI Score 59/100 (Grade B). CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases. Market cap: $3.73B, Sector: Healthcare.
Price live · AI analysis from May 9, 2026Analyst Coverage for CBAY: CBAY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CBAY against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
CBAY: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →CymaBay Therapeutics (CBAY) Healthcare & Pipeline Overview
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for liver and other chronic diseases, primarily primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Their lead product candidate, seladelpar, is currently undergoing Phase III clinical trials, positioning the company to potentially address unmet needs in the liver disease treatment market.
What Is the Investment Thesis for CBAY?
CymaBay Therapeutics presents a notable research candidate centered on the potential of seladelpar, its lead product candidate, to address unmet needs in PBC and NASH. The ongoing Phase III clinical trial for PBC represents a near-term catalyst, with positive results potentially leading to regulatory approval and commercialization. The company's focus on PPARδ agonism offers a differentiated approach in liver disease treatment. Key value drivers include successful trial outcomes, regulatory approvals, and strategic partnerships. However, investors may want to evaluate the risks associated with clinical-stage development, regulatory hurdles, and competition from established pharmaceutical companies. With a market cap of $3.73B and a negative profit margin of -339.1%, the company's valuation is heavily reliant on the successful development and commercialization of its pipeline.
Based on FMP financials and quantitative analysis
CBAY Key Highlights
- Lead product candidate seladelpar is in Phase III clinical study for PBC, representing a significant near-term value driver.
- Gross margin of 97.8% indicates strong potential profitability upon commercialization of successful products.
- Market capitalization of $3.73B reflects investor confidence in the company's pipeline and technology.
- Ongoing Phase 2a clinical study of MBX-2982 for hypoglycemia in type 1 diabetics diversifies the company's pipeline.
- Beta of 0.32 suggests lower volatility compared to the overall market.
Who Are CBAY's Competitors?
CBAY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| IVBXF Innovent Biologics, Inc. | $11.39 | +3.02% | $19.76B | 68 |
| ZYME Zymeworks Inc. | $25.42 | -3.39% | $1.87B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBAY's Key Strengths?
- Lead product candidate seladelpar is in Phase III clinical study for PBC.
- Strong gross margin of 97.8% indicates potential for profitability.
- Focus on unmet needs in liver disease treatment.
- Developing MBX-2982 for hypoglycemia in type 1 diabetics diversifies pipeline.
What Are CBAY's Weaknesses?
- Clinical-stage company with no currently approved products.
- Negative profit margin of -339.1%.
- Reliance on the success of seladelpar.
- Limited revenue streams.
What Could Drive CBAY Stock Higher?
- Completion of Phase III clinical trial for seladelpar in PBC.
- Regulatory submission for seladelpar in PBC.
- Data readouts from Phase 2a clinical study of MBX-2982 for hypoglycemia in type 1 diabetics.
- Potential for strategic partnerships and licensing agreements.
What Are the Key Risks for CBAY?
- Negative return on equity (-64.2%) — the business is not currently generating profit on shareholder capital.
- Clinical trial failures for seladelpar or MBX-2982.
- Regulatory delays or rejection of seladelpar.
- Competition from other companies developing therapies for liver diseases.
- Dependence on the success of seladelpar.
- Patent expiration and generic competition.
What Are the Growth Opportunities for CBAY?
- Seladelpar for Primary Biliary Cholangitis (PBC): The successful completion of the Phase III clinical trial for seladelpar in PBC represents a significant growth opportunity. PBC is a chronic liver disease with limited treatment options, creating a substantial unmet need. Positive trial results could lead to regulatory approval and commercialization, potentially generating significant revenue for CymaBay. The market for PBC treatments is estimated to reach billions of dollars, offering a substantial revenue opportunity. Timeline: Anticipated completion of Phase III trial in the near term.
- Seladelpar for Nonalcoholic Steatohepatitis (NASH): While seladelpar has completed Phase 2b clinical study for NASH, further development in this indication represents a significant growth opportunity. NASH is a rapidly growing liver disease with no approved therapies, creating a large and underserved market. Successful development of seladelpar for NASH could generate substantial revenue for CymaBay. The market for NASH treatments is projected to reach tens of billions of dollars. Timeline: Dependent on future clinical trial plans and regulatory strategy.
- MBX-2982 for Hypoglycemia in Type 1 Diabetics: The ongoing Phase 2a clinical study of MBX-2982 for hypoglycemia in type 1 diabetics represents a diversification opportunity for CymaBay. Hypoglycemia is a common and potentially dangerous complication of type 1 diabetes, creating a need for improved treatments. Successful development of MBX-2982 could generate revenue in a different therapeutic area. The market for hypoglycemia treatments is estimated to be significant. Timeline: Dependent on clinical trial results and regulatory strategy.
- Strategic Partnerships and Licensing Agreements: CymaBay's existing license agreement with ABW Cyclops SPV LP and worldwide license from Janssen Pharmaceuticals, Inc. demonstrate the potential for strategic partnerships and licensing agreements to drive growth. These collaborations can provide access to new technologies, funding, and markets. Further strategic partnerships could accelerate the development and commercialization of CymaBay's pipeline. Timeline: Ongoing, with potential for new partnerships in the future.
- Expansion into New Indications: CymaBay's expertise in liver disease and metabolic disorders could be leveraged to expand into new indications. The company could explore the development of therapies for other liver diseases, such as autoimmune hepatitis or alcoholic liver disease. Expansion into new indications would diversify the company's pipeline and reduce its reliance on seladelpar. Timeline: Long-term, dependent on research and development efforts.
What Opportunities Does CBAY Have?
- Successful completion of Phase III trial for seladelpar in PBC.
- Regulatory approval and commercialization of seladelpar.
- Expansion into new indications, such as NASH.
- Strategic partnerships and licensing agreements.
What Threats Does CBAY Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Patent expiration and generic competition.
What Are CBAY's Competitive Advantages?
- Patent protection on seladelpar and other drug candidates.
- Clinical data supporting the safety and efficacy of their therapies.
- Expertise in PPARδ agonism and liver disease biology.
- Established relationships with key opinion leaders and regulatory agencies.
What Does CBAY Do?
CymaBay Therapeutics, Inc., founded in 1988 and headquartered in Newark, California, is a biopharmaceutical company dedicated to the development and delivery of innovative therapies for the treatment of liver and other chronic diseases. Originally incorporated as Metabolex, Inc., the company has evolved to focus on addressing unmet medical needs in hepatology and related fields. CymaBay's lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta (PPARδ), currently in Phase III clinical development for the treatment of primary biliary cholangitis (PBC). Seladelpar has also completed a Phase 2b clinical study for patients with nonalcoholic steatohepatitis (NASH). In addition to seladelpar, CymaBay is developing MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. The company operates under a license agreement with ABW Cyclops SPV LP to support the development of seladelpar for PBC. Furthermore, CymaBay holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds targeting an undisclosed metabolic disease. CymaBay's pipeline reflects its commitment to advancing novel therapies for chronic diseases with significant patient impact.
What Products and Services Does CBAY Offer?
- Develop therapies for liver diseases like primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).
- Focus on PPARδ (peroxisome proliferator-activated receptor delta) agonists.
- Conduct clinical trials to evaluate the safety and efficacy of their drug candidates.
- Seek regulatory approval from agencies like the FDA to commercialize their therapies.
- Engage in research and development to discover new drug candidates.
- Collaborate with other companies and research institutions to advance their pipeline.
- Develop therapies for metabolic disorders such as hypoglycemia in type 1 diabetics.
How Does CBAY Make Money?
- Develop and commercialize pharmaceutical products for liver and other chronic diseases.
- Generate revenue through the sale of approved therapies.
- Out-license or partner with other companies to develop and commercialize their products.
- Fund research and development through venture capital and public offerings.
What Industry Does CBAY Operate In?
CymaBay Therapeutics operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. The market for liver disease treatments is substantial, driven by the increasing prevalence of conditions such as PBC and NASH. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing novel therapies. CymaBay's focus on PPARδ agonism positions it to potentially capture a significant share of the liver disease treatment market, provided it can successfully navigate the clinical and regulatory hurdles. The industry is subject to stringent regulatory requirements and evolving treatment paradigms.
Who Are CBAY's Key Customers?
- Patients suffering from primary biliary cholangitis (PBC).
- Patients suffering from nonalcoholic steatohepatitis (NASH).
- Patients suffering from hypoglycemia in type 1 diabetics.
- Healthcare providers who prescribe medications for these conditions.
FY2026 estForward Outlook
Wall Street analysts project CymaBay Therapeutics revenue of about $269.8M for fiscal 2026, with EPS near $-0.06. The estimate reflects 7 contributing analysts.
CBAY Valuation & Market Position
With a $3.73B market cap, CymaBay Therapeutics sits in the mid-cap segment of the market. Relative to its peer group, CBAY's quantitative score of 59/100 is below the peer average of 73/100.
ROE -64%Key Financial Metrics
Return on equity for CymaBay Therapeutics stands at -64.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -24.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 10.96 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.1%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 4/9Financial Health
CymaBay Therapeutics's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 12.89 places it in the safe zone, indicating low near-term bankruptcy risk.
Company Profile
CymaBay Therapeutics operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newark, US. The company is led by CEO Sujal A. Shah. CBAY has traded publicly since 2014.
CBAY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests those in the know see long-term value, aligning interests with shareholders.
- Positive community chatter indicates growing confidence in CymaBay's pipeline and potential market impact.
- Favorable market perception of their lead drug candidate seladelpar, particularly for PBC treatment, boosts optimism.
- Strong community belief in the company's management team and their ability to execute on strategic goals.
Bear Case
- Limited insider selling activity raises concerns about near-term growth prospects.
- Negative community sentiment reflects worries about potential regulatory hurdles for seladelpar approval.
- Market perception suggests uncertainty surrounding the competitive landscape and CymaBay's ability to maintain market share.
- Community concerns about the company's long-term financial stability and ability to fund ongoing research and development.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
CBAY Latest News
-
Stocks That Hit 52-Week Lows On Friday
benzinga · May 6, 2022
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Apr 27, 2022
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 10, 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· Oct 9, 2019
CBAY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CBAY.
Price Targets
Wall Street price target analysis for CBAY.
CBAY MoonshotScore
What does this score mean?
The MoonshotScore rates CBAY's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sujal A. Shah
CEO
Sujal A. Shah serves as the Chief Executive Officer of CymaBay Therapeutics, bringing extensive experience in the biopharmaceutical industry. His background includes leadership roles in various pharmaceutical companies, where he focused on strategic planning, business development, and commercialization. Shah's expertise spans across multiple therapeutic areas, including liver disease and metabolic disorders. He has a proven track record of driving growth and innovation in the biopharmaceutical sector. His educational background includes advanced degrees in relevant scientific and business disciplines, equipping him with a comprehensive understanding of the industry's complexities.
Track Record: Under Sujal A. Shah's leadership, CymaBay Therapeutics has focused on advancing seladelpar through clinical development, particularly in PBC. Key milestones include initiating and progressing the Phase III clinical trial for seladelpar in PBC and advancing MBX-2982 into Phase 2a clinical study for hypoglycemia in type 1 diabetics. He has also overseen strategic partnerships and licensing agreements to support the company's growth and pipeline expansion.
What Investors Ask About CymaBay Therapeutics (CBAY) — Healthcare
What does CymaBay Therapeutics, Inc. do?
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for liver and other chronic diseases. Their lead product candidate, seladelpar, is a selective agonist of peroxisome proliferator activated receptor delta (PPARδ) that is in Phase III clinical study for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. CymaBay aims to address unmet medical needs in hepatology and related fields through innovative therapies.
What do analysts say about CBAY stock?
Analyst coverage of CymaBay Therapeutics (CBAY) reflects a focus on the potential of seladelpar in treating PBC and NASH. Key valuation metrics include price targets based on projected revenue from seladelpar, discounted cash flow analysis, and comparisons to peer companies. Growth considerations center on the successful completion of clinical trials, regulatory approvals, and commercialization efforts. Analyst consensus typically reflects optimism regarding the potential of seladelpar, but also acknowledges the risks associated with clinical-stage development and regulatory uncertainty. The stock's performance is closely tied to clinical trial results and regulatory milestones.
What are the main risks for CBAY?
The primary risks for CymaBay Therapeutics (CBAY) revolve around the clinical development and regulatory approval of seladelpar. Clinical trial failures or delays could significantly impact the company's valuation and future prospects. Regulatory hurdles and potential rejection of seladelpar by the FDA represent another significant risk. Competition from established pharmaceutical companies and other biotechnology firms developing therapies for liver diseases also poses a threat. Furthermore, the company's reliance on the success of seladelpar makes it vulnerable to setbacks in its lead program. Patent expiration and the potential for generic competition represent long-term risks.
What are the key factors to evaluate for CBAY?
CymaBay Therapeutics (CBAY) holds an AI score of 59/100 (moderate). Not financial advice.
How frequently does CBAY data refresh on this page?
CBAY prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CBAY's recent stock price performance?
CymaBay Therapeutics (CBAY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Lead product candidate seladelpar is in Phase III clinical study for PBC. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CBAY overvalued or undervalued right now?
Valuing CymaBay Therapeutics (CBAY) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CBAY?
Before investing in CymaBay Therapeutics (CBAY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-05-09.
- Clinical trial outcomes are inherently uncertain.
- Regulatory approvals are subject to change.